Literature DB >> 8822119

Hepatic lesions of vascular origin in multicentric Castleman's disease, plasma cell type: report of one case with peliosis hepatis and another with perisinusoidal fibrosis and nodular regenerative hyperplasia.

T Molina1, A Delmer, A Le Tourneau, P Texier, C Degott, J Audoin, R Zittoun, J Diebold.   

Abstract

We report two cases of multicentric Castleman's disease, plasma cell type, associated with three different liver lesions. Peliosis hepatis was observed in one case and perisinusoidal fibrosis with nodular regenerative hyperplasia in the other. These observations give some evidence that Castleman's disease, per se, may be involved in these three presumably interrelated liver vascular lesions. These changes, already described in monoclonal lymphoproliferations such as myeloma and Waldenström's disease, may also be recorded in a disease characterized by a strong polyclonal plasma cell hyperplasia.

Entities:  

Mesh:

Year:  1995        PMID: 8822119     DOI: 10.1016/s0344-0338(11)80662-x

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  3 in total

1.  Nodular regenerative hyperplasia of the liver and Castleman's disease: potential role of interleukin-6.

Authors:  Ayako Kiyuna; Takashi Sunagawa; Akira Hokama; Masato Touyama; Ryosaku Tomiyama; Hiroshi Sakugawa; Fukunori Kinjo; Atsushi Saito
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

Review 2.  Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension.

Authors:  Marek Hartleb; Krzysztof Gutkowski; Piotr Milkiewicz
Journal:  World J Gastroenterol       Date:  2011-03-21       Impact factor: 5.742

3.  Liver cirrhosis in a child associated with Castleman's disease: A case report.

Authors:  Soya Kobayashi; Ayano Inui; Tomoyuki Tsunoda; Syuichiro Umetsu; Tsuyoshi Sogo; Masaaki Mori; Masato Shinkai; Tomoo Fujisawa
Journal:  World J Clin Cases       Date:  2020-05-06       Impact factor: 1.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.